XNCR Quote, Financials, Valuation and Earnings

Glaukos Corp. has a net margin of -28.7% compared to Xencor, Inc.'s net margin of -12.16%. Xencor, Inc.'s return on equity of -20.07% beat Glaukos Corp.'s return on equity of -11.73%.

Xencor, Inc. has a consensus price target of $28.25, signalling upside risk potential of 82.85%. On the other hand Glaukos Corp. has an analysts' consensus of $124.07 which suggests that it could grow by 6.37%. Given that Xencor, Inc. has higher upside potential than Glaukos Corp., analysts believe Xencor, Inc. is more attractive than Glaukos Corp..

Xencor, Inc. has a beta of 0.960, which suggesting that the stock is 3.97% less volatile than S&P 500. In comparison Glaukos Corp. has a beta of 0.692, suggesting its less volatile than the S&P 500 by 30.762%.

Xencor, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Glaukos Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Xencor, Inc. pays -- of its earnings as a dividend. Glaukos Corp. pays out -- of its earnings as a dividend.

Xencor, Inc. quarterly revenues are $21M, which are smaller than Glaukos Corp. quarterly revenues of $133.5M. Xencor, Inc.'s net income of -$6M is higher than Glaukos Corp.'s net income of -$16.2M. Notably, Xencor, Inc.'s price-to-earnings ratio is -- while Glaukos Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Xencor, Inc. is 7.60x versus 14.08x for Glaukos Corp.. Usually stocks with elevated PS ratios are considered overvalued.

GT Biopharma, Inc. has a net margin of -28.7% compared to Xencor, Inc.'s net margin of --. Xencor, Inc.'s return on equity of -20.07% beat GT Biopharma, Inc.'s return on equity of -626.24%.

Xencor, Inc. has a consensus price target of $28.25, signalling upside risk potential of 82.85%. On the other hand GT Biopharma, Inc. has an analysts' consensus of $8.00 which suggests that it could grow by 846.75%. Given that GT Biopharma, Inc. has higher upside potential than Xencor, Inc., analysts believe GT Biopharma, Inc. is more attractive than Xencor, Inc..

Xencor, Inc. has a beta of 0.960, which suggesting that the stock is 3.97% less volatile than S&P 500. In comparison GT Biopharma, Inc. has a beta of 1.524, suggesting its more volatile than the S&P 500 by 52.367%.

Xencor, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. GT Biopharma, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Xencor, Inc. pays -- of its earnings as a dividend. GT Biopharma, Inc. pays out -- of its earnings as a dividend.

Xencor, Inc. quarterly revenues are $21M, which are larger than GT Biopharma, Inc. quarterly revenues of --. Xencor, Inc.'s net income of -$6M is lower than GT Biopharma, Inc.'s net income of -$3.1M. Notably, Xencor, Inc.'s price-to-earnings ratio is -- while GT Biopharma, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Xencor, Inc. is 7.60x versus 59.35x for GT Biopharma, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Ironwood Pharmaceuticals, Inc. has a net margin of -28.7% compared to Xencor, Inc.'s net margin of 32.84%. Xencor, Inc.'s return on equity of -20.07% beat Ironwood Pharmaceuticals, Inc.'s return on equity of --.

Xencor, Inc. has a consensus price target of $28.25, signalling upside risk potential of 82.85%. On the other hand Ironwood Pharmaceuticals, Inc. has an analysts' consensus of $2.50 which suggests that it could fall by -23.31%. Given that Xencor, Inc. has higher upside potential than Ironwood Pharmaceuticals, Inc., analysts believe Xencor, Inc. is more attractive than Ironwood Pharmaceuticals, Inc..

Xencor, Inc. has a beta of 0.960, which suggesting that the stock is 3.97% less volatile than S&P 500. In comparison Ironwood Pharmaceuticals, Inc. has a beta of 0.177, suggesting its less volatile than the S&P 500 by 82.259%.

Xencor, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ironwood Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Xencor, Inc. pays -- of its earnings as a dividend. Ironwood Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Xencor, Inc. quarterly revenues are $21M, which are smaller than Ironwood Pharmaceuticals, Inc. quarterly revenues of $122.1M. Xencor, Inc.'s net income of -$6M is lower than Ironwood Pharmaceuticals, Inc.'s net income of $40.1M. Notably, Xencor, Inc.'s price-to-earnings ratio is -- while Ironwood Pharmaceuticals, Inc.'s PE ratio is 21.10x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Xencor, Inc. is 7.60x versus 1.63x for Ironwood Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Nuvalent, Inc. has a net margin of -28.7% compared to Xencor, Inc.'s net margin of --. Xencor, Inc.'s return on equity of -20.07% beat Nuvalent, Inc.'s return on equity of -38.24%.

Xencor, Inc. has a consensus price target of $28.25, signalling upside risk potential of 82.85%. On the other hand Nuvalent, Inc. has an analysts' consensus of $141.71 which suggests that it could grow by 33.99%. Given that Xencor, Inc. has higher upside potential than Nuvalent, Inc., analysts believe Xencor, Inc. is more attractive than Nuvalent, Inc..

Xencor, Inc. has a beta of 0.960, which suggesting that the stock is 3.97% less volatile than S&P 500. In comparison Nuvalent, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Xencor, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nuvalent, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Xencor, Inc. pays -- of its earnings as a dividend. Nuvalent, Inc. pays out -- of its earnings as a dividend.

Xencor, Inc. quarterly revenues are $21M, which are larger than Nuvalent, Inc. quarterly revenues of --. Xencor, Inc.'s net income of -$6M is higher than Nuvalent, Inc.'s net income of -$122.4M. Notably, Xencor, Inc.'s price-to-earnings ratio is -- while Nuvalent, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Xencor, Inc. is 7.60x versus -- for Nuvalent, Inc.. Usually stocks with elevated PS ratios are considered overvalued.